A phase II trial to investigate the efficacy of sulfatinib in patients with neuroendocrine tumours

Trial Profile

A phase II trial to investigate the efficacy of sulfatinib in patients with neuroendocrine tumours

Planning
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Sulfatinib (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jul 2017 According to a Chi-Med media release, company expects to initiate this trial in late 2017 or early 2018.
    • 02 Aug 2016 According to a Chi-Med media release, the company expects to initiate this trial in 2017 based on the conclusion of the phase I dose-escalation trial (see CT profile 700260954).
    • 21 Mar 2016 According to a Chi-Med media release, this trial is expected to be initiated in the second half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top